AG
NGM

Artal Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Artal Group’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100,000
Closed -$1.46M – 117
2019
Q2 		$1.46M Buy
+100,000
New +$1.46M 0.06% 97

Other funds holding NGM

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
JRP
Jasper Ridge Partners Menlo Park, California $4.69B AUM 31.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artal Group's NGM Position: Q3 2019 in Review

Artal Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2019, closing a stake of 100,000 shares — an estimated $1.46M sold.

Artal Group first reported a position in NGM in Q2 2019 and held it in 1 quarter. The position peaked at $1.46M in Q2 2019. 51 funds tracked by Wall St. Rank hold NGM as of Q3 2019.

  • Artal Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Artal Group sold 100,000 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $1.46M.
  • Artal Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Artal Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.46M in Q2 2019.
  • 51 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Artal Group's 13F filing for Q3 2019, filed 14 Nov 2019.